AstraZeneca's Lynparza meets primary endpoint in Phase III trial to treat ovarian cancer

AstraZeneca's Lynparza (olaparib) has met its primary endpoint in the Phase III SOLO-2 clinical trial for the treatment of patients with germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news